Published in Osteoporos Int on October 22, 2010
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
Recommendations for preventing fracture in long-term care. CMAJ (2015) 1.62
Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J (2011) 1.11
Comparison between various fracture risk assessment tools. Osteoporos Int (2014) 1.00
Competing mortality and fracture risk assessment. Osteoporos Int (2012) 0.99
Performance of risk assessment instruments for predicting osteoporotic fracture risk: a systematic review. Osteoporos Int (2013) 0.93
A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos (2016) 0.92
Patient perceptions of provider barriers to post-fracture secondary prevention. Osteoporos Int (2014) 0.86
An economic evaluation: Simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures. J Bone Miner Res (2013) 0.82
Fracture risk in long term care: a systematic review and meta-analysis of prospective observational studies. BMC Geriatr (2014) 0.81
Fracture risk assessment after BMD examination: whose job is it, anyway? Osteoporos Int (2014) 0.81
Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted? Osteoporos Int (2012) 0.79
A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy. Curr Oncol (2011) 0.79
A comparative study of using non-hip bone density inputs with FRAX®. Osteoporos Int (2011) 0.79
Fragility fracture: recent developments in risk assessment. Ther Adv Musculoskelet Dis (2015) 0.78
Estimating osteoporotic fracture risk following a wrist fracture: a tale of two systems. Arch Osteoporos (2015) 0.77
Osteoporosis prescribing in long-term care: impact of a provincial knowledge translation strategy. Can J Aging (2015) 0.77
Patients do not have a consistent understanding of high risk for future fracture: a qualitative study of patients from a post-fracture secondary prevention program. Osteoporos Int (2015) 0.77
Multisite quantitative ultrasound for the prediction of fractures over 5 years of follow-up: the Canadian Multicentre Osteoporosis Study. J Bone Miner Res (2013) 0.76
Partnership for fragility bone fracture care provision and prevention program (P4Bones): study protocol for a secondary fracture prevention pragmatic controlled trial. Implement Sci (2013) 0.76
What Do We Know about Individuals Who Are Assessed as Being at Moderate Risk for Future Fracture in Canada? Health (Irvine Calif) (2015) 0.75
A practical approach to osteoporosis management in the geriatric population. Can Geriatr J (2015) 0.75
Screening, assessment, and treatment of osteoporosis for the nurse practitioner: key questions and answers for clinical practice--a Canadian perspective. J Am Assoc Nurse Pract (2014) 0.75
Bone Mineral Density Reporting Underestimates Fracture Risk in Ontario. Health (Irvine Calif) (2015) 0.75
Direct comparison of FRAX(R) and a simplified fracture risk assessment tool in routine clinical practice: a registry-based cohort study. Osteoporos Int (2016) 0.75
Does regional loss of bone density explain low trauma distal forearm fractures in men (the Mr F study)? Osteoporos Int (2017) 0.75
Equal treatment: no evidence of gender inequity in osteoporosis management in a coordinator-based fragility fracture screening program. Osteoporos Int (2017) 0.75
The diagnosis of osteoporosis. J Bone Miner Res (1994) 10.90
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int (1998) 7.14
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med (2008) 5.05
A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92
Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med (2004) 3.93
A reference standard for the description of osteoporosis. Bone (2007) 3.67
FRAX and its applications to clinical practice. Bone (2009) 3.32
Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res (1994) 3.29
Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int (2001) 3.23
International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res (2002) 3.14
Trends in hip fracture rates in Canada. JAMA (2009) 2.95
A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res (2004) 2.92
Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J (2005) 2.15
Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res (2010) 1.90
Low bone mineral density and fracture burden in postmenopausal women. CMAJ (2007) 1.81
Validation of an electronic, population-based prescription database. Ann Pharmacother (1998) 1.45
Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab (2006) 1.39
Population-based Canadian hip fracture rates with international comparisons. Osteoporos Int (2009) 1.36
Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int (2010) 1.25
Construction and validation of a population-based bone densitometry database. J Clin Densitom (2005) 1.24
Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int (2010) 1.24
Association between change in BMD and fragility fracture in women and men. J Bone Miner Res (2009) 1.19
Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom (2007) 1.15
Repeat low-trauma fractures occur frequently among men and women who have osteopenic BMD. J Bone Miner Res (2009) 1.15
Simplified system for absolute fracture risk assessment: clinical validation in Canadian women. J Bone Miner Res (2009) 1.13
Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Med Care (1999) 1.07
Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum (2000) 1.01
Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res (2009) 1.00
Establishing a regional bone density program: lessons from the Manitoba experience. J Clin Densitom (2003) 1.00
A population-based study of osteoporosis testing and treatment following introduction of a new bone densitometry service. Osteoporos Int (2004) 0.90
The importance of spectrum bias on bone density monitoring in clinical practice. Bone (2006) 0.86
Simplified 10-year absolute fracture risk assessment: a comparison of men and women. J Clin Densitom (2010) 0.84
Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet (1995) 7.17
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17
Analysis of 1.9 Mb of contiguous sequence from chromosome 4 of Arabidopsis thaliana. Nature (1998) 5.91
Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int (2009) 5.43
Sequence and analysis of chromosome 4 of the plant Arabidopsis thaliana. Nature (1999) 5.03
Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med (2007) 4.68
Bulk and rhizosphere soil bacterial communities studied by denaturing gradient gel electrophoresis: plant-dependent enrichment and seasonal shifts revealed. Appl Environ Microbiol (2001) 4.28
Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med (1995) 3.92
Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ (2000) 3.77
Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys (1989) 3.33
The glycemic index: methodology and clinical implications. Am J Clin Nutr (1991) 3.24
Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med (1987) 3.13
Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med (1998) 2.95
DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet (1984) 2.92
The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Ann Intern Med (1990) 2.89
HIV infection does not require endocytosis of its receptor, CD4. Cell (1988) 2.88
Current and projected rates of hip fracture in Canada. CMAJ (1997) 2.85
IOF position statement: vitamin D recommendations for older adults. Osteoporos Int (2010) 2.79
Back to the future: the pyramids of rheumatoid arthritis. J Rheumatol (1997) 2.76
Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum (2006) 2.73
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69
Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int (2001) 2.67
Light-induced superconductivity in a stripe-ordered cuprate. Science (2011) 2.54
Targeted expression of constitutively active receptors for parathyroid hormone and parathyroid hormone-related peptide delays endochondral bone formation and rescues mice that lack parathyroid hormone-related peptide. Proc Natl Acad Sci U S A (1997) 2.52
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone (2003) 2.51
A conformal index (COIN) to evaluate implant quality and dose specification in brachytherapy. Int J Radiat Oncol Biol Phys (1998) 2.42
First direct observation of a nearly ideal graphene band structure. Phys Rev Lett (2009) 2.41
Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2000) 2.40
N of 1 randomized trials for investigating new drugs. Control Clin Trials (1990) 2.37
The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int (2001) 2.32
Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci U S A (2001) 2.30
Antidepressant medication use and breast cancer risk. Am J Epidemiol (2000) 2.29
The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med (1994) 2.08
Extracorporeal photopheresis in the treatment of AIDS-related complex: a pilot study. Ann Intern Med (1990) 2.08
Myosin conformational states determined by single fluorophore polarization. Proc Natl Acad Sci U S A (1998) 2.07
Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J Cell Biol (1994) 2.00
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab (2000) 2.00
Amino-acid sequence of equine renal metallothionein-1B. Proc Natl Acad Sci U S A (1976) 1.99
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Abnormalities identified in the knees of asymptomatic volunteers using peripheral magnetic resonance imaging. Osteoarthritis Cartilage (2005) 1.98
Cancer registration in Ontario: a computer approach. IARC Sci Publ (1991) 1.97
Reinforcement of self-directed learning and the development of professional attitudes through peer- and self-assessment. Acad Med (1998) 1.95
Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ (2000) 1.94
Why multilayer graphene on 4H-SiC(0001[over ]) behaves like a single sheet of graphene. Phys Rev Lett (2008) 1.92
Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proc Natl Acad Sci U S A (2001) 1.88
The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2008) 1.86
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Augmented trochanteric bone mineral density after modified physical education classes: a randomized school-based exercise intervention study in prepubescent and early pubescent children. J Pediatr (2000) 1.85
The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone (2004) 1.84
Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract (2012) 1.84
Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2001) 1.83
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
The osteoporosis care gap in Canada. BMC Musculoskelet Disord (2004) 1.81
Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum (1993) 1.80
Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int (2007) 1.79
Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol (1991) 1.78
The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int (2012) 1.76
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol (1992) 1.75
Identification of adenylate cyclase-stimulating activity and cytochemical glucose-6-phosphate dehydrogenase-stimulating activity in extracts of tumors from patients with humoral hypercalcemia of malignancy. Proc Natl Acad Sci U S A (1983) 1.75
Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. Mol Cell Biol (1995) 1.73
Metabolic acidosis in the alcoholic: a pathophysiologic approach. Metabolism (1983) 1.70
Scalable templated growth of graphene nanoribbons on SiC. Nat Nanotechnol (2010) 1.66
Effect of brain-derived neurotrophic factor treatment and forced arm use on functional motor recovery after small cortical ischemia. Stroke (2004) 1.66
Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res (1988) 1.66
Association of chronic urticaria and angioedema with thyroid autoimmunity. Arch Dermatol (1983) 1.65
Long-term (4- to 6-year) outcome of Palmaz-Schatz stenting: paucity of late clinical stent-related problems. J Am Coll Cardiol (1996) 1.65
Estimation of creatinine clearance in elderly persons in long-term care facilities. Am J Med (2001) 1.64
Cloning and targeted deletion of the mouse fetuin gene. J Biol Chem (1997) 1.64
Evidence for a humoral mechanism for enhanced osteogenesis after head injury. J Bone Joint Surg Am (1990) 1.64
Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol (2011) 1.62
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61
Termination of mammalian rDNA replication: polar arrest of replication fork movement by transcription termination factor TTF-I. Cell (1997) 1.61
An epidemiologic study of hip fracture in postmenopausal women. Am J Epidemiol (1982) 1.60
[Specific interference with development and plastid enzyme formation in higher plants by elevated growth temperature]. Z Naturforsch B (1969) 1.60
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Comparison of self-reported and physician-reported antidepressant medication use. Ann Epidemiol (1999) 1.60
Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int (2000) 1.59
Hypoxia-activated apoptosis of cardiac myocytes requires reoxygenation or a pH shift and is independent of p53. J Clin Invest (1999) 1.58
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia (2004) 1.57
Prevalence of IgA-antiendomysial antibody in asymptomatic low bone mineral density. Am J Gastroenterol (2001) 1.54
Lymphedema in the developing and developed world: contrasts and prospects. Lymphology (1988) 1.53